It has been estimated that 50 million people are infected with the taeniasis/cysticercosis complex in the world today and that 50,000 die each year. It also appears that 350,000 individuals remain infected in Latin America. In Ribeirão Preto, Brazil, neurocysticercosis has been identified in 7.5% of the patients admitted to a ward specialized in the treatment of neurologic diseases. Its clinical manifestations comprise seizures, intracranial hypertension, cysticercotic meningitis, psychiatric symptoms, apoplectic or endarteritic form, and spinal cord syndrome. Lethality of neurocysticercosis varies from 16.4% to 25.9%. Diagnosis is dependent on the results of computed tomography of the brain and examination of the cerebrospinal fluid. Lately, albendazole in association with steroids has been elected the treatment of choice for neurocysticercosis. In the authors' opinion, compulsory notification of cases and preventive measures should be implemented. In Brazil, in the absence of a centralized program of control, regional initiatives should be stimulated, keeping in mind WHO's advice: "Think globally, act locally".
Neurocysticercosis; Taeniasis; Albendazole; Computed tomography
